|
Schizophrenia
|
0.320 |
GeneticVariation
|
disease |
BEFREE |
Participants included 62 outpatients diagnosed with schizophrenia (placebo n = 31; oxytocin n = 31) who received 36 IU BID, with supervised administration 45 min prior to sessions on CBSST group therapy days.
|
30180918 |
2019 |
|
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
Eligible patients with no prior systemic therapy for advanced HCC and Child-Pugh A to B7 were treated with sorafenib 400 mg BID and escalating doses of cixutumumab (2, 4, or 6 mg/kg IV weekly) in a 3 + 3 design.
|
29520435 |
2018 |
|
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
BEFREE |
The RP2D was tivantinib 360 mg BID and sorafenib 400 mg BID for all cancer histologies, except in hepatocellular carcinoma (HCC) patients tivantinib was 240 mg BID plus sorafenib 400 mg BID.
|
25294187 |
2015 |
|
Schizophrenia
|
0.320 |
Biomarker
|
disease |
PSYGENET |
Decreases in BH3 interacting domain death agonist (BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the OFC.
|
22545112 |
2012 |
|
Schizophrenia
|
0.320 |
AlteredExpression
|
disease |
BEFREE |
Decreases in BH3 interacting domain death agonist (BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the OFC.
|
22545112 |
2012 |
|
Liver carcinoma
|
0.320 |
Biomarker
|
disease |
CTD_human |
Bid sensitizes apoptosis induced by chemotherapeutic drugs in hepatocellular carcinoma.
|
15289866 |
2004 |
|
Bipolar Disorder
|
0.310 |
Biomarker
|
disease |
PSYGENET |
Decreases in BH3 interacting domain death agonist (BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the OFC.
|
22545112 |
2012 |
|
Bipolar Disorder
|
0.310 |
AlteredExpression
|
disease |
BEFREE |
Decreases in BH3 interacting domain death agonist (BID) mRNA transcript levels were found in the schizophrenia and bipolar disorder groups affecting both the DLPFC and the OFC.
|
22545112 |
2012 |
|
Malignant neoplasm of stomach
|
0.310 |
Biomarker
|
disease |
CTD_human |
The data suggest that such mutations occur rarely in gastric cancers and that only a small fraction of BID mutations may lead to the loss of its apoptotic function.
|
15095271 |
2004 |
|
Malignant neoplasm of stomach
|
0.310 |
Biomarker
|
disease |
BEFREE |
Inactivating mutation of the pro-apoptotic gene BID in gastric cancer.
|
15095271 |
2004 |
|
Stomach Neoplasms
|
0.300 |
Biomarker
|
group |
CTD_human |
Inactivating mutation of the pro-apoptotic gene BID in gastric cancer.
|
15095271 |
2004 |
|
Hereditary Diffuse Gastric Cancer
|
0.300 |
Biomarker
|
disease |
CTD_human |
Inactivating mutation of the pro-apoptotic gene BID in gastric cancer.
|
15095271 |
2004 |
|
Bronchopulmonary Dysplasia
|
0.200 |
Biomarker
|
disease |
RGD |
Neonatal bronchopulmonary dysplasia increases neuronal apoptosis in the hippocampus through the HIF-1α and p53 pathways.
|
26431790 |
2016 |
|
Myocardial Reperfusion Injury
|
0.200 |
Biomarker
|
phenotype |
RGD |
Inhibition of cytochrome c release by 10-N-nonyl acridine orange, a cardiolipin-specific dye, during myocardial ischemia-reperfusion in the rat.
|
19940077 |
2010 |
|
Reperfusion Injury
|
0.200 |
Biomarker
|
disease |
RGD |
Effects of a semi-synthetic N-,O-sulfated glycosaminoglycan K5 polysaccharide derivative in a rat model of cerebral ischaemia/reperfusion injury.
|
19888517 |
2009 |
|
Myocardial Reperfusion Injury
|
0.200 |
Biomarker
|
phenotype |
RGD |
Different signaling pathways induce apoptosis in endothelial cells and cardiac myocytes during ischemia/reperfusion injury.
|
11934844 |
2002 |
|
Body mass index
|
0.100 |
GeneticVariation
|
phenotype |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
Leukemia, Myelocytic, Acute
|
0.100 |
GeneticVariation
|
disease |
GWASCAT |
Genome-wide haplotype association study identify the FGFR2 gene as a risk gene for acute myeloid leukemia.
|
27903959 |
2017 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
The effects of cisplatin include activation of caspases, proteolysis of enzyme poly ADP ribose polymerase (PARP), control of apoptosis modulators B-cell lymphoma 2 (Bcl-2), Bcl-2-associated X protein (Bax), and BH3-interacting domain death agonist (Bid), and cell cycle arrest in G2/M phase.
|
30845773 |
2019 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Importantly, pBD129 elevated the expression level of Bcl-2-associated death promoter (Bcl-2), but down-regulated the expression levels of apoptosis-related genes such as the B-cell lymphoma-2-associated X protein (Bax), BH3-interacting domain death agonist (Bid), cysteinyl aspartate-specific proteinase-3 (Caspase-3), and caspase-9 in the intestinal mucosa (<i>P</i> < 0.05).
|
31636641 |
2019 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
Combination treatment reduced the expression of B-cell lymphoma 2 (BCL2), BH3 interacting domain death agonist (BID), and BCL-x/L.
|
30343279 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, the pro‑apoptotic factors Bcl‑2 X‑associated protein and BH3 interacting domain death agonist were uregulated, while the anti‑apoptotic factors B‑cell lymphoma 2 (Bcl‑2) and Bcl‑2‑extra large were downregulated.
|
29363721 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
Furthermore, our data revealed that Z-IETD-FMK also blocked increase of truncated BH3 interacting domain death agonist (tBID)/BID, decrease of the B-cell lymphoma 2 (Bcl-2)/Bcl-2 associate X protein (Bax) ratio and mitochondrial membrane potential (MMP), release of cytochrome c, as well as cleavage of caspase-9/3 and poly (ADP-ribose) polymerase (PARP) induced by Cd.
|
29891925 |
2018 |
|
B-Cell Lymphomas
|
0.080 |
AlteredExpression
|
group |
BEFREE |
The results showed that poly (I:C) transfection markedly induced HeLa apoptosis, increased the protein levels of pro‑apoptotic B cell lymphoma‑2 (Bcl‑2)‑associated X protein (Bax) and BH3 interacting‑domain death agonist (Bid), and suppressed the protein expression levels of anti‑apoptotic Bcl‑2 and Survivin.
|
26848042 |
2016 |
|
B-Cell Lymphomas
|
0.080 |
Biomarker
|
group |
BEFREE |
These observations were found to correlate with increases in truncated BH3 interacting‑domain death agonist and B‑cell lymphoma 2 (Bcl‑2) interacting mediator of cell death, but not Bcl‑2 homologous antagonist killer, Bcl‑2‑associated X protein, Bcl‑2, B‑cell lymphoma‑extra large and induced myeloid leukemia cell differentiation protein levels.
|
24270523 |
2014 |